Education and Training
5HT3 Antagonists to Treat Opioid Withdrawal and to Prevent the Progression of Physical Dependence
Opioid medications are commonly used for pain relief. When given over time, physical dependence can occur. This results in unpleasant side effects (such as agitation and nausea) if opioid medications are suddenly stopped. This study aims to test the use of the drug ondansetron to reduce the symptoms associated with opioid withdrawal and to prevent the progression of opioid physical dependence, thereby allowing future investigators to better test the role of physical dependence in the development of addiction and also possibly improving acceptance of abstinence-based programs for addiction.
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Ondansetron
- drug: Placebo
- drug: Morphine
- drug: Naloxone 0.4 mg/70 kg
- drug: Naloxone 0.8 mg/70 kg
Eligibility
Inclusion Criteria:
- Diagnosis of chronic low-back pain and who may be taking up to 30 mg equivalent of
morphine per day (such as Vicodin, Percocet, etc)
- 18-60 years old
- Eligible to escalate opioid therapy dose, as determined by the treating physician or
PI
- At low risk for addiction as determined by the PI and an addiction expert, Dr. Ian
Carroll.
Exclusion Criteria:
- History of cardiovascular disease
- History of peripheral neuropathic pain, scleroderma, or other condition that would
preclude cold water forearm immersion
- History of addiction or chronic pain conditions other than low-back pain, d) history
of cardiac arrhythmia
- History of hepatic disease
- Use of steroid or nerve-stimulating medications
- Any condition precluding opioid use
- Pregnancy
Ages Eligible for Study
18 Years - 60 Years
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Larry Chu, MD, MS
650-724-2970
Not Recruiting